My wife and I recently had to decide what we wanted to do with our health insurance for 2010, and it really made me think hard about the way we understand the finances of and how we pay for healthcare as individuals.

We have a fairly unique PPO-type plan that gives us a $2,000 budget to spend as a family – on doc visits, lab tests, drugs, etc.  We don’t pay for a single co-pay or for a drug or a test until we utilize $2,000 worth of services.  Everything from $2,000-$6,000 comes out of our pocket, and then after that $6,000 threshold, we would have to pay for everything else 100%.  Not too bad, especially for healthy individuals, right?

But, what if ended up using more than that $2,000 budget? We’d be on the hook for 100% of our costs up to $6,000.  The alternative insurance plan we were weighing against included co-pays as our only costs with the plan. Period – no other hidden costs (or so it was our impression). We wondered whether there was a chance that if we had chosen the alternative plan, even despite making the co-pay payments all year, that it would have actually been cheaper over the course of the year to just pay for the co-pays out of pocket? We wanted to understand at what financial point would our co-pays and all the out of pocket expenses under the alternative plan actually be better than getting our “free care” up to $2,000?  A break-even point, if you will.

Well, as it turns out, it’s literally 100% impossible to answer that question.

It wasn’t possible for us to make a real informed decision as to which plan would have been right for us.  I see the dermatologist 4-5 times a year and a general practitioner about once for a cold.  My wife has regular check-ups and maybe visits the doc 2-3 times a year.  But we each might have a few tests here and there or a minor ‘procedure’ at one of these visits.  Given that, we wanted to know how quickly we’d burn through the $2,000 budget.

Given all that, we called the insurance company and asked to get an estimate of what our costs would be, which would then allow us to make an informed decision. I asked about specific acne treatments at the dermatologist and my wife asked about other doc visit costs.  The insurance company literally refused to release those financial figures.  We couldn’t do basic estimations on visits and yearly costs because the insurance company wouldn’t release the figures.  They said something about costs varying on a per-provider (doctor or facility) basis and pharmacy.  Each time one of us called there was a new or different excuse as to why they couldn’t make the costs transparent.  Sounded like a lot of fudging to us.

We got the distinct sense (and from talking to others, we’re not the only ones) that the insurance company was deliberately throwing up smoke screens and trying to be opaque.  Whenever a system actually strives to be opaque regarding costs or hides facts, that’s a red flag to me that something’s up. Certainly from the way the insurance companies are acting, it seems as if they are better off at keeping us all in the dark.  The less the public knows, the better. Confusion seems to be a key component to the insurance industry’s business proposition and model.

My sense is that the system as a whole would be a lot more efficient and effective with greater transparency and improved business models.  I’m going to follow up on this with upcoming posts on how healthcare IT and new healthcare polices would be able to not only improve our care, but make our system more efficient and actually save money.  My upcoming posts are going to address that exact fact, look at how the system can be more transparent, why it’s failed in the past and how several different types of business models in the healthcare and insurance industries might actually make sense.

As I’m pulling those posts together I’d love to hear from you!  What do you think?  What have you noticed about your insurance company that might be a bit odd or difficult?

{ 0 comments }

Biotech and Bioinformatics Meet-up in San Francisco!

by Bradley Miller on January 19, 2010

UPDATE: Please RSVP to: windmiller [at] gmail

This Wednesday night – January 20th at 7pm I’ll be hosting what I hope will be the first of many meet-ups for entrepreneurially minded biotech and bioinformatics people here in San Francisco.  It’ll be at Crossroads Café in SOMA. In February the meetup will most likely be moved to a more permanent location at i/o Ventures, a start-up incubator space in the city.  Information will be updated on the meet-up’s page on Medicine Think and on my @medicinethink Twitter account (follow me!).  Feel free to pass this info on to interested friends.

Genome Valance by Ben Fry.  Ben's expertise is helping to graphically represent and interpret massive data sets and information.  This piece represents genomic analysis using BLAST.  More from Ben at http://benfry.com/genomevalence/ (click to enlarge)

Genome Valance by Ben Fry. Ben's expertise is helping to graphically represent and interpret massive data sets and information. This piece represents genomic analysis using BLAST. I picked this piece specifically because it takes a new look at how to represent and understand genomics and informatics - something I hope this meetup will help to encourage more of. More about his work from Ben at http://benfry.com/genomevalence/ (click to enlarge)

So, why the meetup?  I’ve spent the past 4 years in San Francisco in both the tech and biotech realms.  Actually, I’ve been a passively active member of the tech community – out of interest I go to events and meetups with friends.  I meet people through my wife who’s in tech PR.  I’m actually pretty well immersed in the community without really trying that hard – it’s a pretty open and warm community.

But as I’ve actively tried to network and attend events in the biotech and genomics space, it’s been much more difficult.  While I’m just about one or two degrees from most of the tech crowd here in SF, I can’t say the same about the biotech space.  And, perhaps with some good reason – the biotech/life science/genomics space rely pretty heavily on intellectual property and trade secrets, so that stunts people’s ability to be social.  Despite that, I think there’s much more room for building a more solid general community outside of the big players and established start-ups.

One of the beautiful things about the tech community in SF is the intermingling of different specialties and cross-pollination of ideas.  This leads to start-ups, improved technologies and a more healthy and vibrant tech community.  Often, these ideas, through start-ups, are passed up to the larger players through acquisitions – so from early start-ups to big behemoths the entire community benefits from this networking and open community.

The biotech community here could use more of this attitude and community.  San Francisco and the University of California has made a substantial investment in the Mission Bay neighborhood – there are very, very few areas in the country that have the foundation for success as does this very special part of SF.  And with visionary institutes like QB3, which is based at UCSF and Berkeley, I see a whole new generation of PhD and other grad students with an entrepreneurial energy that hasn’t been created at other campuses.  Combine that with Stanford’s legacy of doing the same thing and you’ve got the seeds for an amazing industry and community.

Don’t get me wrong, the Bay Area is already a leader in biotech – clearly there’s a lot going on.  But to take it to the next level, the community also has to kick it up a notch.  I hope this meet-up can serve as a partial catalyst (of course, there will need to be many, many more events, etc) to tap in to both the tech and biotech communities here and bring together a diverse and energetic crowd.  Ideally, I’d like to promote an interdisciplinary meetup – between not only biotech and bioinformatics people, but to bring in members of the tech community.  I think tech could greatly inform how bioinformatics and biotech does business – from improving how data is handled, to user interface and analytics and beyond – there is much room for tech to impact the biotech community.  And, to a certain extent, tech would also benefit from some of the thinking from leaders in biotech.  From algorithm and natural language specialties, to managing massive data sets and making meaning, to scalable software, SF and Silicon Valley is well positioned to inform biotech and informatics and help solidify the Bay Area as a leader in biotech and informatics.

If you’re in SF or the surrounding areas, please come by Wednesday at 7 to the Crossroads Café. Even if you are a tech person with a curiosity about biotech, genomics, personal medicine and the like, without a super deep background or expertise, we’d love to have you.  I think these two groups have much to learn from each other and that this type of social interaction will lead to new ideas, energy and companies that will help take the Bay Area to the next level and retain a leadership in the life sciences.

What do you think?  What would you like to see at these types of meetups?

{ 0 comments }

New Starts for a New Year – Becoming an Entrepreneur

January 6, 2010

In the past I wrote about getting a start-up off the ground. More precisely, about how to take an idea and give it legs and maybe get it running – how to mold an idea and begin to improve it. I call this socializing the idea (with the next steps being socializing the [...]

Read the full article →

Cancer Advances – Something old and Something New

December 30, 2009

An interesting article appeared on NYTimes.com today that deals with “new” old approaches to the cancer thought and research paradigm. In essence, the article points to research that indicates cancer is more than just a group of genetic mutations – it’s also caused by the tiny interactions of proteins and other parts of the cell [...]

Read the full article →

Curing Cancer Through a Shift in Perspective

December 14, 2009

How we frame and think about subjects clearly has an impact on how we approach and attempt to solve problems.  The first image, right or wrong, that comes to my mind is Apple’s “Think Different” campaign back in the mid 1990s. But I’m talking about the importance of perspective in a much bigger sense – [...]

Read the full article →

How Much Data is in a Cell?- Post Thanksgiving Fun

December 1, 2009

It’s been a rough week so far – been stumbling out of my Thanksgiving food coma. So, it seems like the right time for a light, quick and fun post. Last week I came across a really interesting site from the genetics group at the University of Utah. It is a fantastic [...]

Read the full article →

Hospitals Need More than Political Reform – Healthcare Quality v Spending pt 2

November 19, 2009

My last post dove in to healthcare quality versus spending and introduced the Dartmouth Atlas as one of the key insight tools we have for healthcare spending and quality here in the US.  Essentially the Atlas takes a look at the entire country’s healthcare spending by using Medicare claim data as a proxy.  From this [...]

Read the full article →

Healthcare Quality Vs Spending – Pt. 1

November 16, 2009

Because of all the recent debate on healthcare reform, there’s been a lot of attention on healthcare costs and quality.  A NYTimes Magazine article this last Sunday focused on the evolving principles of effective healthcare spending. Specifically, the article focused on changing physician behavior toward using the most efficient and effective care techniques, rather [...]

Read the full article →

Personal Genetics – Why 23&Me Doesn’t Work

November 5, 2009

In PEHub yesterday an article about 23&Me and the financial issues it’s been having.  As an entrepreneur and having had plenty of great ideas poo-poo’ed by investors and industry folks alike, it’s really hard for me to understand why anyone would have invested in 23&Me as a company.  What I don’t understand is why highly [...]

Read the full article →

The Genomics of Cancer and Why It Matters

October 29, 2009
Thumbnail image for The Genomics of Cancer and Why It Matters

One of the most harrowing experiences of medical school was during a surgery for a gynecologic oncology patient.  Prior to the operation we had absolutely no idea that this woman’s ovarian cancer had spread – we had only detected a spot on her left ovary.  However, during surgery we discovered that her cancer had metastasized [...]

Read the full article →